SMI.LONDON

Pullman London St Pancras **25 June 2025**



www.smi.london

Soft Mist Inhaler; **Make It Better**

Welcome to SMI.London 2025, the 3rd annual conference dedicated to Soft Mist Inhalers (SMIs) where we'll continue the SMI conversation, started back in 2023. Today, you'll explore how to make, develop, and apply SMIs, learn how to measure and model their performance, and understand their strategic role within an inhaled therapy portfolio.

SMI.London is the only event dedicated to soft mist inhalers in the world! We are delighted to see you today in London to build the future of SMIs together. In the UK, the number of SMI prescriptions is already outpacing nebuliser ones and it's only a matter of time before SMIs are on par with DPIs and gradually replace pMDIs with a true low-global-warming-potential pedigree. This is a group effort and we all have a role to play to achieve this.

We're thrilled to welcome an inspiring lineup of speakers who will share the latest developments in their work. SMI.London 2025 has been thoughtfully curated to showcase how soft mist inhalers are emerging as a key player alongside other inhalation devices, highlighting the unique benefits they offer.

Today's focus: exploring the science of aerosols and their practical applications.

The speakers and session chairs at SMI.London 2025 are key opinion leaders with extensive experience in the field of inhaled drug delivery. We are most grateful they accepted to speak and chair sessions.

SMI.London 2025 is a place to learn and to meet each other, if you do not know someone, go and say hello!

This event is made possible thanks to the support of the Exhibitors, Speakers and our Media Partners; do thank them.

The summary of the conference will be available after the event at **WWW.SMI.LONDON**

Have a great day. See you next year?

We are grateful for the support of our Media Partners:

ON drugDELIVERY

IPI
International Pharmaceutical Industry

Inhalation

The conversation doesn't end here;
Join us online on LinkedIn

8:00 **Registration, refreshments and networking**

9:00

Introducing SMI.London 2025

Dr. Philippe Rogueda, Chief Business Officer, Merxin Ltd

9:15

Speed Networking

- Talk to your neighbours.
- Greet people you have never met before.

Chair of the session: Mr. Chris Vernall, Director, CV Respiratory

9:30

Exploring Nasal siRNA-LNP SMI Therapies

Professor Daniela Traini, Professor of Respiratory Science, Woolcock Institute of Medical Research, Macquarie University & Ab Initio Pharma

- Role of siRNA in treating respiratory diseases.
- Limitations of current delivery methods.
- Rationale for using lipid nanoparticles (LNPs) and SMI nasal delivery.
- In Vitro Assessment of Aerosol Performance.
- In Vivo Evaluation in an infected animal model.

Thank you to our Exhibitors:











10:15

LNPs & SMIs: Extending Formulation & Treatment Options

Dr. Rémi Rosière, Chief Scientific Officer, Co-founder, InhaTarget Therapeutics

- Combination of LNP and SMI as a promising pulmonary drug delivery platform.
- Potential drug cargo for inhalation and new indications.
- LNP formulation options for multiple drug cargo.
- Focus on inhaled immunotherapy for lung cancers.

10:45 **Coffee break & networking**

Chair of the session: Dr. Peter Hirst, Consultant, Peter Hirst Consulting Ltd

11:15

Seeing Through The Mist: SMI Spray Characterization

Dr. Deborah Jones, Director of Sales, EMEIA, Proveris Laboratories

- Importance of automated actuation for testing for SMI devices.
- Considerations for Spray Characterizations testing of SMI products.
- Additional learnings from the use of "Playback" tools.
- Plume Front Velocity and Spray Duration measurements for novel drugs and generics Deposition tools for SMI.
- Deposition tools for SMI.

Thank you to our Exhibitors:

H&T PRESSPART

intertek

Total Quality. Assured.

Nanopharm

an Aptar pharma company

TUN ABDUL RAZAK RESEARCH CENTRE
MALAYSIAN RUBBER BOARD

Rubber Consultants

11:45

Aseptic Filling Machine: Development Step To Commercial Production

Mrs. Laury Livemont, Industrial Development Manager, Unither Pharmaceuticals

- Enhancing drug safety with AFM through closed system sterile filling.
- Exploring therapeutic applications made possible by AFM technology.
- Driving formulation and testing.
- Scaling up from formulation to industrial production.
- Sterility or low bioburden as CQA for the finished product.

12:15

Innovating Spray Nozzle Technology: How Microfluidic Manufacturing Drives Precision

Dr.-Ing, Christian Walk (Business Development Manager) & Dr. Marko Blom (Chief Technology Officer), Micronit B.V.

- Soft Mist Spray nozzles.
- Colliding Jet.
- Rayleigh Jet.
- Nozzle Manufacturing.
- Silicon and Glass.

12:45 **Lunch, exhibition and networking**

Thank you to our Exhibitors:

MERXIN®
WE MAKE INHALERS

micronit

invox

GAPLAST
novel solutions for all senses

Chair of the session: Dr. Jenny Lam, Associate Professor of Pharmaceutics, UCL School of Pharmacy

14:00

Aerosolization Of Wegovy® With MRX004 (SMI)

Dr. Philippe Rogueda, Chief Business Officer, Merxin Ltd

- Wegovy® commercial injection formulations were successfully aerosolised with MRX004.
- The integrity of Semaglutide was preserved on aerosolisation.
- The FPF of Wegovy® 0.25mg/05ml in MRX004 was 53% with a FPD 3 µg.
- The FPF of Semaglutide 10 mg/ml in MRX004 was 52% with a FPD of 55 µg.
- Inhaled drug delivery of GLP-1 analogues is a viable alternative to injections.

14:30

Expanding The SMI World: Options & Applications

Dr. Nicolas Buchmann, Chief Technology Officer, Resyca B.V.

- Principles of Pre-Filled Syringe Soft Mist Inhaler, advantages of an integrated primary package.
- SMIs as an option for the delivery of delicate biologics.
- Re-purposing existing drugs for improved delivery and patient comfort.
- Extending soft mist principles to nasal delivery, enabling effective CNS therapies.

Thank you to our Exhibitors:

MICROSOL

THE SMI POWERHOUSE

MIKRON AUTOMATION

CHROMCORE LIFESCIENCES LLP

Harro Höfliger

15:00

Links Between Solution Properties, Spray and Lung Deposition in Soft Mist Inhalers

Dr. Khaled Alzahabi, Nasal & Pulmonary Drug Delivery Formulation Specialist, Nanopharm Ltd, an Aptar Pharma Company

The goal of this study was to understand design space and understand lung deposition of these tricker systems.

As we move towards formulating more complex molecules into SMIs (think larger biological molecules, polymeric excipients, higher concentrations etc.) we are going to end up with wider ranges in formulation physical properties such as viscosity and surface tension.

Solutions with a range of non-Newtonian rheology and different surface tensions were prepared to see which ones we could spray out of a Respimat SMI.

We measured the spray properties (droplet size, velocity, spray pattern) of this that aerosolised.

These data were then input into our deposition models to understand how this all links to lung deposition.

15:30 **Coffee Break & Networking**

Chair of the session: Mr. Chris Hall, Chairman, Merxin Ltd

16:00 **Panel Discussion & Final Remarks**

17:00 **Close of the day**

The conversation doesn't end here; Join us online on LinkedIn

Have a great day. See you next year?

SMI.London 2025, an event planned and coordinated by Merxin Ltd

www.merxin.com We Make Inhalers

We will ask the speakers to share their slides after the event, subscribe to the Merxin Ltd newsletter to know when they will be available.

Wi-Fi : Conference-Pullman
Password : Meeting1

To follow conference news and conversations please use:

THE SMI POWERHOUSE

REVOLUTIONISING INHALED DRUG DELIVERY

Through The SMI Powerhouse, Merxin Ltd and OECHSLERhealth are actively transforming the landscape for inhaled drug developers. We're empowering you with faster access to market-ready SMI devices by directly addressing critical needs.

This isn't just a partnership; it's a strategic alliance.

REDUCED TIME TO MARKET

ENHANCED RELIABILITY

WIDENED ACCESS TO SUPERIOR DRUG DELIVERY

OPTIMISED COSTS

INFO@THESMIPOWERHOUSE.COM

MERXIN® WE MAKE INHALERS

OECHSLERhealth

MERXIN®
WE MAKE INHALERS

WE MAKE IT BETTER.


WE WILL LAUNCH YOU

Merxin Ltd's MRX004 delivers therapies successfully and effectively to the lungs for local and systemic action.

MRX004 is a proven and tested Soft Mist Inhaler. Get in touch at info@merxin.com to try it with your molecules.



MRX004.COM



www.smi.london